MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Brandon Capital, Australasia’s leading life sciences venture capital firm, today announces the successful exit of its portfolio company Myricx Bio following its agreement to be acquired by Novartis. The transaction is valued at up to US$1.5 billion (~A$2.16bn) including an upfront cash payment of US$1.1 billion (~A$1.58bn) plus potential milestone payments.
Read more at globenewswire.comBrandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics
Barchart·07/06/2026 00:08:00
語音播報
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.